Non-small cell lung cancer+2
RecruitingStudy on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations
Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage IIIA+1
- Substances:Amivantamab
Belgium- Participants:18–64 years · 65+ years
- Substances:Amivantamab
- Sponsor:Universitaetsklinikum Essen AöR














